Development of GnRH antagonists for prostate cancer: new approaches to treatment.
about
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapyApoptotic death of prostate cancer cells by a gonadotropin-releasing hormone-II antagonist.The potential regulatory mechanisms of the gonadotropin-releasing hormone in gonadotropin transcriptions identified with bioinformatics analyses.Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.Cetrorelix in the treatment of female infertility and endometriosis.Differentially expressed miRNAs after GnRH treatment and their potential roles in FSH regulation in porcine anterior pituitary cellTherapeutic potential of GnRH antagonists in the treatment of precocious puberty.Controversies surrounding androgen deprivation for prostate cancer.GnRH antagonists in the treatment of infertility.Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer.Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.Benign prostatic hyperplasia: an insight into current investigational medical therapies.Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia.GnRH agonist therapy in a patient with recurrent ovarian granulosa cell tumors.Assessment of fertility in male rats after extended chemical castration with a GnRH antagonist.Trinucleotide repeats and protein folding and disease: the perspective from studies with the androgen receptor.Degarelix for prostate cancer.Degarelix and its therapeutic potential in the treatment of prostate cancer.Decapeptyl ameliorates cyclophosphamide-induced reproductive toxicity in male Balb/C mice: histomorphometric, stereologic and hormonal evidences.Luteinizing hormone-releasing hormone antagonists.Degarelix: a review of its use in patients with prostate cancer.GnRH and GnRH receptors in the pathophysiology of the human female reproductive system.Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.Leuprolide-induced myopathy.Therapeutic outcomes of the LHRH antagonists.
P2860
Q28829239-CA4AEA68-AF92-47D7-95D4-BF14DCD6156BQ33754466-56DCEFCC-793D-4FE4-931C-E83F12B730FAQ33809076-CDAEBAB4-DA70-4569-95C7-4665B3AB0144Q33904772-ED118F8A-CF0D-40A3-864E-084846B764F6Q34101055-7FE226CB-EEBE-4D24-94DB-AD2B55AD5C20Q34571550-90762710-7280-4646-9C81-440E3889EB8EQ34603126-FE14C82F-0AD7-4FAC-80D5-C135869644B0Q34841773-CEAD9B4B-8992-44CE-8B5B-BE9CE2CBBCB6Q34849222-9E27E8F3-FAA4-44F1-A99F-0C3DFC0D967EQ35597631-23B45B02-E4CF-413B-A15B-D14214E067F8Q35906945-C56F0501-B555-485F-8247-7BC9CC0211B8Q36024462-BAE41497-30AB-46C8-8A92-06B3A9B2D0D6Q36300022-898A3392-FAA7-4F33-B1BD-18BA86DDA089Q36677464-0ED12B06-95AE-4ED6-B435-113E4623712FQ36916873-3F3B1C6F-A299-4920-9149-0047FD618959Q37232116-185C73CD-149D-47E3-919D-2546291936FFQ37361444-80C23DDC-99D1-4098-AC7D-34E223D6104CQ37474263-480F6ECE-C478-409F-959B-938E7A4527D2Q37488225-FB295158-1727-4364-A96B-71216E9087F2Q37510637-79B70CF9-9749-44AB-B2FF-059345C28710Q37615348-48887977-C955-48F5-9E26-B96939A3DFA3Q37638747-34A66D60-4737-47E4-8AF1-64D6FBE07DC5Q38206404-8C4502AE-07B8-4A41-8138-53168CE9D8FBQ38682630-69F650D5-5BA4-4C35-9FE1-1852135F2634Q38798811-F90DC536-3883-4D7A-A32B-7232E31DD929Q39236911-E9970352-60C5-454E-9F52-4D6CFF08705FQ41559413-95578473-1462-4A01-81DC-92377BDEB36AQ44169499-2647F506-E78B-4ABF-A5E7-151CB4553DA4Q47859553-04953B4D-D903-4C3F-9538-55ED49522C6D
P2860
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
@ast
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
@en
type
label
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
@ast
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
@en
prefLabel
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
@ast
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
@en
P1433
P1476
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
@en
P2093
P304
P356
10.1634/THEONCOLOGIST.5-2-162
P577
2000-01-01T00:00:00Z